

### **Amendments to the Claims**

This listing of claims replaces all prior versions, and listings, of claims in the above-identified application:

#### **Listing of Claims**

1.     **(Previously Presented)** A method of inducing a cytokine in a cell, the method comprising contacting the cell with an immunological regulator under conditions effective to induce a cytokine, wherein the immunological regulator consists of MQPPPLP (SEQ ID NO:1), an active analog thereof, and combinations thereof, wherein the active analog comprises a peptide having an amino acid sequence with at least about 15 percent proline and having at least about 70 percent sequence identity to SEQ ID NO:1.
2.     **(Original)** The method of claim 1 wherein the cell is present in a cell culture, a tissue, an organ, or an organism.
3.     **(Original)** The method of claim 1 wherein the cell is a mammalian cell.
4.     **(Original)** The method of claim 3 wherein the cell is a human cell.
5.     **(Cancelled)**
6.     **(Previously Presented)** A method for modulating an immune response in a cell, the method comprising contacting the cell with an immunological regulator under conditions effective to induce a cytokine, wherein the immunological regulator consists of MQPPPLP (SEQ ID NO:1), an active analog thereof, and combinations thereof, wherein the active analog comprises a peptide having an amino acid sequence with at least about 15 percent proline and having at least about 70 percent sequence identity to SEQ ID NO:1.

7. **(Original)** The method of claim 6 wherein the cell is present in a cell culture, a tissue, an organ, or an organism.
8. **(Original)** The method of claim 6 wherein the cell is a mammalian cell.
9. **(Original)** The method of claim 8 wherein the cell is a human cell.
10. **(Cancelled)**
11. **(Previously Presented)** A method for modulating an immune response in a patient, the method comprising administering to the patient an immunological regulator under conditions effective to induce a cytokine, wherein the immunological regulator consists of MQPPPLP (SEQ ID NO:1), an active analog thereof, and combinations thereof, wherein the active analog comprises a peptide having an amino acid sequence with at least about 15 percent proline and having at least about 70 percent sequence identity to SEQ ID NO:1.
12. **(Cancelled)**
13. **(Original)** The method of claim 11 wherein the immunological regulator is administered as part of a dietary supplement.
14. **(Original)** The method of claim 11 wherein the immunological regulator is administered topically.
15. **(Original)** The method of claim 11 wherein the patient is an animal.
16. **(Original)** The method of claim 15 wherein the patient is a human.

17. **(Original)** The method of claim 11 wherein the immune response is a specific immune response.

18. **(Original)** The method of claim 11 wherein the immune response is a nonspecific immune response.

19. **(Original)** The method of claim 11 wherein the immune response is the interferon response or antibody production.

20. **(Previously Presented)** A method for modulating leukocyte proliferation, the method comprising contacting leukocytes with a leukocyte regulator selected from the group of colostrinin, a constituent peptide thereof, an active analog thereof, and combinations thereof, under conditions effective to change the number of leukocytes; wherein the active analog comprises a peptide having an amino acid sequence with at least about 15 percent proline and having at least about 70 percent sequence identity to one or more constituent peptides of colostrinin, which are selected from the group of SEQ ID NO:1 through SEQ ID NO:34.

21. **(Previously Presented)** The method of claim 20 wherein the leukocytes are present in a cell culture or an organism.

22. **(Previously Presented)** The method of claim 20 wherein the leukocytes are mammalian cells.

23. **(Previously Presented)** The method of claim 22 wherein the leukocytes are human cells.

24. **(Previously Presented)** The method of claim 22 wherein the leukocytes are increased in number.

25. **(Previously Presented)** The method of claim 24 wherein the leukocytes are differentiated.
26. **(Previously Presented)** The method of claim 22 wherein the leukocyte regulator is a constituent peptide of colostrinin.
27. **(Currently Amended)** The method of claim 26 wherein the leukocyte regulator is selected from the group consisting of MQPPPLP (SEQ ID NO:1), LQTPQPLLQVMMEPQGD (SEQ ID NO:2), DQPPDVEKPDLPFQVQS (SEQ ID NO:3), LFFFLPVVNVLP (SEQ ID NO:4), DLEMPVLPVEFPFV (SEQ ID NO:5), MPQNFYKLPQM (SEQ ID NO:6), VLEMKFPPPPQETVT (SEQ ID NO:7), LKPFPKLKVEVFPFP (SEQ ID NO:8), VVMEV (SEQ ID NO:9), SEQP (SEQ ID NO:10), DKE (SEQ ID NO:11), FPPPK (SEQ ID NO:12), DSQPPV (SEQ ID NO:13), DPPPPQS (SEQ ID NO:14), SEEMP (SEQ ID NO:15), KYKLQPE (SEQ ID NO:16), VLPPNVG (SEQ ID NO:17), VYPFTGPIPN (SEQ ID NO:18), SLPQNILPL (SEQ ID NO:19), TQTPVVVPPF (SEQ ID NO:20), LQPEIMGVPKVKETMVPK (SEQ ID NO:21), HKEMPFPKYPVEPFTESQ (SEQ ID NO:22), SLTLTDVEKLHLPLPLVQ (SEQ ID NO:23), SWMHQPP (SEQ ID NO:24), QPLPPTVMFP (SEQ ID NO:25), PQSVLS (SEQ ID NO:26), LSQPKVLPVPQKAVPQRDMPIQ (SEQ ID NO:27), AFLLYQE (SEQ ID NO:28), RGPFPILV (SEQ ID NO:29), ATFNRYQDDHGEEILKSL (SEQ ID NO:30), VESYVPLFP (SEQ ID NO:31), FLLYQEPVLGPVR (SEQ ID NO:32), LNF (SEQ ID NO:33), and MHQPPQPLPPTVMFP (SEQ ID NO:34), an active analog thereof, and combinations thereof; wherein the active analog comprises a peptide having an amino acid sequence with at least about 15 percent proline and having at least about 70 percent sequence identity to one or more constituent peptides of colostrinin, which are selected from the group of SEQ ID NO:1 through SEQ ID NO:34.
28. **(Currently Amended)** The method of claim 27 wherein the leukocyte regulator is selected from the group consisting of MQPPPLP (SEQ ID NO:1), LQTPQPLLQVMMEPQGD

(SEQ ID NO:2), DQPPDVEKPDLPFQVQS (SEQ ID NO:3), LFFFLPVVNVLP (SEQ ID NO:4), DLEMPVLPVEPFPFV (SEQ ID NO:5), MPQNFYKLPQM (SEQ ID NO:6), VLEMKFPPPPQETVT (SEQ ID NO:7), LKPFKPKLKEVFPEP (SEQ ID NO:8), YPFTGPIPN (SEQ ID NO:18), SLPQNILPL (SEQ ID NO:19), TQTPVVVPPF (SEQ ID NO:20), HKEMPFKYPVEPFOTESQ (SEQ ID NO:22), and combinations thereof.

29. **(Currently Amended)** A method for modulating leukocyte proliferation in a patient, the method comprising administering to the patient a leukocyte regulator selected from the group consisting of colostrinin, a constituent peptide thereof, an analog thereof, and combinations thereof, under conditions effective to change the number of leukocytes; wherein the active analog comprises a peptide having an amino acid sequence with at least about 15 percent proline and having at least about 70 percent sequence identity to one or more constituent peptides of colostrinin, which are selected from the group of SEQ ID NO:1 through SEQ ID NO:34.

30. **(Original)** The method of claim 29 wherein the patient is a human.

31. **(Previously Presented)** The method of claim 29 wherein the leukocytes are increased in number.

32. **(Previously Presented)** The method of claim 31 wherein the leukocytes are differentiated.

33. **(Previously Presented)** The method of claim 29 wherein the leukocyte regulator is a constituent peptide of colostrinin.

34. **(Currently Amended)** The method of claim 33 wherein the leukocyte regulator is selected from the group consisting of MQPPPLP (SEQ ID NO:1), LQTPQPLLQVMMEPQGD (SEQ ID NO:2), DQPPDVEKPDLPFQVQS (SEQ ID NO:3), LFFFLPVVNVLP (SEQ ID

NO:4), DLEMPVLPVEPFPPFV (SEQ ID NO:5), MPQNFYKLPQM (SEQ ID NO:6), VLEMKFPPPPQETVT (SEQ ID NO:7), LKPFPKLKVEVFPPF (SEQ ID NO:8), VVMEV (SEQ ID NO:9), SEQP (SEQ ID NO:10), DKE (SEQ ID NO:11), FPPPK (SEQ ID NO:12), DSQPPV (SEQ ID NO:13), DPPPPQS (SEQ ID NO:14), SEEMP (SEQ ID NO:15), KYKLQPE (SEQ ID NO:16), VLPPNVG (SEQ ID NO:17), VYPFTGPIPN (SEQ ID NO:18), SLPQNILPL (SEQ ID NO:19), TQTPVVVPPF (SEQ ID NO:20), LQPEIMGVPKVKETMVPK (SEQ ID NO:21), HKEMPFPKYPVEPFTESQ (SEQ ID NO:22), SLTLTDVEKLHLPLPLVQ (SEQ ID NO:23), SWMHQPP (SEQ ID NO:24), QPLPPTVMFP (SEQ ID NO:25), PQSVLS (SEQ ID NO:26), LSQPKVLPVPQKAVPQRDMPIQ (SEQ ID NO:27), AFLLYQE (SEQ ID NO:28), RGPFPILV (SEQ ID NO:29), ATFNRYQDDHGEEILKSL (SEQ ID NO:30), VESYVPLFP (SEQ ID NO:31), FLLYQEPVLGPVR (SEQ ID NO:32), LNF (SEQ ID NO:33), and MHQPPQPLPPTVMFP (SEQ ID NO:34), an active analog thereof, and combinations thereof; wherein the active analog comprises a peptide having an amino acid sequence with at least about 15 percent proline and having at least about 70 percent sequence identity to one or more constituent peptides of colostrinin, which are selected from the group of SEQ ID NO:1 through SEQ ID NO:34.

35. **(Currently Amended)** The method of claim 34 wherein the leukocyte regulator is selected from the group consisting of MQPPPLP (SEQ ID NO:1), LQTPQPLLQVMMEPQGD (SEQ ID NO:2), DQPPDVEKPDLPFQVQS (SEQ ID NO:3), LFFFLPVVNVLP (SEQ ID NO:4), DLEMPVLPVEPFPPFV (SEQ ID NO:5), MPQNFYKLPQM (SEQ ID NO:6), VLEMKFPPPPQETVT (SEQ ID NO:7), LKPFPKLKVEVFPEP (SEQ ID NO:8), VYPFTGPIPN (SEQ ID NO:18), SLPQNILPL (SEQ ID NO:19), TQTPVVVPPF (SEQ ID NO:20), HKEMPFPKYPVEPFTESQ (SEQ ID NO:22), and combinations thereof.

36. **(Cancelled)**

37. **(Previously Presented)** A method of inducing a cytokine in a cell, the method comprising contacting the cell with an immunological regulator under conditions effective to induce a cytokine, wherein the immunological regulator is a constituent peptide of colostrinin selected from the group consisting of LQTPQPLLQVMMEPQGD (SEQ ID NO:2), DQPPDVEKPDLPFQVQS (SEQ ID NO:3), LFFFLPVVNVLP (SEQ ID NO:4), DLEMPVLPVEPFPPFV (SEQ ID NO:5), MPQNFYKLPQM (SEQ ID NO:6), VLEMKFPPPPQETVT (SEQ ID NO:7), LKFPKCLKVEVFPFP (SEQ ID NO:8), VVMEV (SEQ ID NO:9), SEQP (SEQ ID NO:10), DKE (SEQ ID NO:11), FPPPK (SEQ ID NO:12), DSQPPV (SEQ ID NO:13), DPPPPQS (SEQ ID NO:14), SEEMP (SEQ ID NO:15), KYKLQPE (SEQ ID NO:16), VLPPNVG (SEQ ID NO:17), VYPFTGPIPN (SEQ ID NO:18), SLPQNILPL (SEQ ID NO:19), TQTPVVVPPF (SEQ ID NO:20), LQPEIMGVPKVKETMVPK (SEQ ID NO:21), HKEMPFKYPVEPFTESQ (SEQ ID NO:22), SLTLTDVEKLHLPLPLVQ (SEQ ID NO:23), SWMHQPP (SEQ ID NO:24), QPLPPTVMFP (SEQ ID NO:25), PQSVLS (SEQ ID NO:26), LSQPKVLPVPQKAVPQRDMPIQ (SEQ ID NO:27), AFLLYQE (SEQ ID NO:28), RGPFPILV (SEQ ID NO:29), ATFNRYQDDHGEEILKSL (SEQ ID NO:30), FLLYQEPVLGPVR (SEQ ID NO:32), LNF (SEQ ID NO:33), and MHQPPQPLPPTVMFP (SEQ ID NO:34), an active analog thereof, and combinations thereof, wherein the active analog comprises a peptide having an amino acid sequence with at least about 15 percent proline and having at least about 70 percent sequence identity to a one or more constituent peptides of colostrinin which are selected from the group of SEQ ID NO:2-30 and 32-34.

38. **(Previously Presented)** A method for modulating an immune response in a cell, the method comprising contacting the cell with an immunological regulator under conditions effective to induce a cytokine, wherein the immunological regulator is a constituent peptide of colostrinin selected from the group consisting of LQTPQPLLQVMMEPQGD (SEQ ID NO:2), DQPPDVEKPDLPFQVQS (SEQ ID NO:3), LFFFLPVVNVLP (SEQ ID NO:4), DLEMPVLPVEPFPPFV (SEQ ID NO:5), MPQNFYKLPQM (SEQ ID NO:6), VLEMKFPPPPQETVT (SEQ ID NO:7), LKFPKCLKVEVFPFP (SEQ ID NO:8), VVMEV

(SEQ ID NO:9), SEQP (SEQ ID NO:10), DKE (SEQ ID NO:11), FPPPK (SEQ ID NO:12), DSQPPV (SEQ ID NO:13), DPPPPQS (SEQ ID NO:14), SEEMP (SEQ ID NO:15), KYKLQPE (SEQ ID NO:16), VLPPNVG (SEQ ID NO:17), VYPFTGPIPN (SEQ ID NO:18), SLPQNILPL (SEQ ID NO:19), TQTPVVVPPF (SEQ ID NO:20), LQPEIMGVPKVKETMVPK (SEQ ID NO:21), HKEMPFPKYPVEPFTESQ (SEQ ID NO:22), SLTLTDVEKLHLPLPLVQ (SEQ ID NO:23), SWMHQPP (SEQ ID NO:24), QPLPPTVMFP (SEQ ID NO:25), PQSVLS (SEQ ID NO:26), LSQPKVLPVPQKAVPQRDMPIQ (SEQ ID NO:27), AFLLYQE (SEQ ID NO:28), RGPFPILV (SEQ ID NO:29), ATFNRYQDDHGEEILKSL (SEQ ID NO:30), FLLYQEPVLGPVR (SEQ ID NO:32), LNF (SEQ ID NO:33), and MHQPPQPLPPTVMFP (SEQ ID NO:34), an active analog thereof, and combinations thereof, wherein the active analog comprises a peptide having an amino acid sequence with at least about 15 percent proline and having at least about 70 percent sequence identity to one or more constituent peptides of colostrinin which are selected from the group of SEQ ID NO:2-30 and 32-34.

39. **(Previously Presented)** A method for modulating an immune response in a patient, the method comprising administering to the patient an immunological regulator under conditions effective to induce a cytokine, wherein the immunological regulator is a constituent peptide of colostrinin selected from the group consisting of LQTPQPLLQVMMEPQGD (SEQ ID NO:2), DQPPDVEKPDLPFQVQS (SEQ ID NO:3), LFFFLPVNVLP (SEQ ID NO:4), DLEMPVLPVEPFPFV (SEQ ID NO:5), MPQNFYKLPQM (SEQ ID NO:6), VLEMKFPPPPQETVT (SEQ ID NO:7), LKPFPKLKVEVFPFP (SEQ ID NO:8), VVMEV (SEQ ID NO:9), SEQP (SEQ ID NO:10), DKE (SEQ ID NO:11), FPPPK (SEQ ID NO:12), DSQPPV (SEQ ID NO:13), DPPPPQS (SEQ ID NO:14), SEEMP (SEQ ID NO:15), KYKLQPE (SEQ ID NO:16), VLPPNVG (SEQ ID NO:17), VYPFTGPIPN (SEQ ID NO:18), SLPQNILPL (SEQ ID NO:19), TQTPVVVPPF (SEQ ID NO:20), LQPEIMGVPKVKETMVPK (SEQ ID NO:21), HKEMPFPKYPVEPFTESQ (SEQ ID NO:22), SLTLTDVEKLHLPLPLVQ (SEQ ID NO:23), SWMHQPP (SEQ ID NO:24), QPLPPTVMFP (SEQ ID NO:25), PQSVLS (SEQ ID NO:26), LSQPKVLPVPQKAVPQRDMPIQ (SEQ ID NO:27), AFLLYQE (SEQ ID NO:28),



Serial No.: 09/641,801

Confirmation No.: 5388

Filed: August 17, 2000

For: USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND ANALOGS THEREOF FOR  
INDUCING CYTOKINES

---

RGPFPILV (SEQ ID NO:29), ATFNRYQDDHGEEILKSL (SEQ ID NO:30),  
FLLYQEPVLGPVR (SEQ ID NO:32), LNF (SEQ ID NO:33), and MHQPPQPLPPTVMFP  
(SEQ ID NO:34), an active analog thereof, and combinations thereof, wherein the active analog  
comprises a peptide having an amino acid sequence with at least about 15 percent proline and  
having at least about 70 percent sequence identity to one or more constituent peptides of  
colostrinin which are selected from the group of SEQ ID NO:2-30 and 32-34.